Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 8Sarcoma 3Lymphoma, B-Cell 3Lymphoma 3Prostatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Inhibition, Psychological 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Chordoma 1

Interventions

Doxorubicin 8Cyclophosphamide 8Vincristine 7Prednisone 7Etoposide 6Brentuximab Vedotin 4prednylidene 3etoposide phosphate 3Bortezomib 3pembrolizumab 2deltacortene 2Vorinostat 2Prednisolone 2Ifosfamide 2tazemetostat 1romidepsin 1pirarubicin 1duvelisib 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Nivolumab 1Methylprednisolone 1Methotrexate 1Melphalan 1Lenalidomide 1Lactones 1Gemcitabine 1Everolimus 1Diet, Gluten-Free 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Enteropathy-Associated T-Cell Lymphoma × tazemetostat × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡